SCHEMBL19880326

SCHEMBL19880326

CC(C)C(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)OC2C1O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 5/20 0.49
▸ PDE4B Q07343 5/20 0.49
▸ PDE4C Q08493 5/20 0.49
▸ PDE4D Q08499 5/20 0.49
▸ ADORA2A P29274 2/20 0.42
▸ ADORA2B P29275 2/20 0.42
▸ ADORA3 P0DMS8 2/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ STING1 Q86WV6 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ RAPGEF3 O95398 2/20 0.41
▸ GMNN O75496 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ RAPGEF4 Q8WZA2 1/20 0.41
▸ PRMT5 O14744 2/20 0.41
▸ WDR77 Q9BQA1 2/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10459452 1.00 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL15892163 0.93 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL15850628 0.93 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL6938343 0.89 PDE4A (0.59) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL22984018 0.88 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL9945534 0.88 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL29674419 0.88 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL19509816 0.88 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL19509705 0.88 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL10459187 0.88 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597421-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2020-03-24 — — US disclosed
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. 2018-07-05 — — US disclosed
US-9896472-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2018-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, RNGTT, RNMT PDE4A 3652/4885PDE4B 3841/4885PDE4C 2966/4885
US-10597421-B2 Protected monomer and method of final deprotection for RNA synthesis NSUN2, RNGTT, RNMT PDE4A 3652/4885PDE4B 3841/4885PDE4C 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback